

Clinical Policy: Cenobamate (Xcopri)

Reference Number: ERX.NPA.142

Effective Date: 03.01.20

Last Review Date: 02.22

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Cenobamate (Xcopri[®]) is a voltage-gated sodium channel inhibitor and a positive allosteric modulator of the γ -aminobutyric acid (GABA_A) ion channel.

FDA Approved Indication(s)

Xcopri is indicated for the treatment of partial-onset seizures in adult patients.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Xcopri is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Partial-Onset Seizures (must meet all):

1. Diagnosis of partial-onset seizures;
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 18 years;
4. Failure of two preferred anticonvulsants indicated for partial seizures (*see Appendix B for examples*), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Dose does not exceed 400 mg (2 tablets) per day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Partial-Onset Seizures (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Xcopri for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 400 mg (2 tablets) per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

GABA_A: γ-aminobutyric acid-subtype A

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
carbamazepine (Carbatrol [®] , Epitol [®] , Equetro [®] , Tegretol [®] , Tegretol XR [®])	Refer to prescribing information	Refer to prescribing information
felbamate (Felbatol [®])		
gabapentin (Neurontin [®])		
lamotrigine (Lamictal [®] , Lamictal CD [®] , Lamictal ODT [®] , Lamictal XR [®])		
levetiracetam (Elepsia XR [®] , Keppra [®] , Keppra XR [®] , Roweepra [®] , Spritam [®])		
oxcarbazepine (Oxtellar XR [®] , Trileptal [®])		
phenobarbital (Luminal [®])		
phenytoin (Dilantin [®] , Phenytek [®])		
pregabalin (Lyrica [®] , Lyrica [®] CR)		
tiagabine (Gabitril [®])		
topiramate (Qudexy XR [®] , Topamax [®] , Topamax Sprinkle [®] , Topiragen [®] , Trokendi XR [®])		
valproic acid, divalproex sodium (Depakene [®] , Depakote Sprinkle [®] , Depakote ER [®] , Depakote [®])		
zonisamide (Zonegran [®])		

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Hypersensitivity to cenobamate or any of the inactive ingredients in Xcopri
 - Familial short QT syndrome
- Boxed warning(s): none reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Partial-onset seizures	<p><u>Dose titration:</u> 12.5 mg PO QD for two weeks, then 25 mg PO QD for two weeks, then 50 mg PO QD for two weeks, then 100 mg PO QD for two weeks, then 150 mg PO QD for two weeks</p> <p><u>Maintenance dose:</u> 200 mg PO QD</p>	400 mg/day

Indication	Dosing Regimen	Maximum Dose
	If needed based on clinical response and tolerability, dose may be increased above 200 mg by increments of 50 mg PO QD every two weeks to 400 mg PO QD.	

VI. Product Availability

Tablets: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg

VII. References

1. Xcopri Prescribing Information. Paramus, NJ: SK Life Science, Inc.; April 2021. Available at: <https://www.xcopri.com>. Accessed November 19, 2021.
2. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicenter, double-blind, randomised, placebo-controlled, dose-response trial. *Lancet Neurology*. 2019; published online November 13, 2019; [https://doi.org/10.1016/S1474-4422\(19\)30399-0](https://doi.org/10.1016/S1474-4422(19)30399-0).
3. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. *Neurology*. 2018;91(2):74-81.
4. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy. *Neurology*. 2018;91(2):82-90.
5. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed November 19, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	01.07.20	02.20
1Q 2021 annual review: no significant changes; references reviewed and updated.	10.22.20	02.21
1Q 2022 annual review: no significant changes; references reviewed and updated.	11.19.21	02.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2020 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written

permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.